[go: up one dir, main page]

CL2018003509A1 - Combinaciones farmacéuticas para el tratamiento del cáncer - Google Patents

Combinaciones farmacéuticas para el tratamiento del cáncer

Info

Publication number
CL2018003509A1
CL2018003509A1 CL2018003509A CL2018003509A CL2018003509A1 CL 2018003509 A1 CL2018003509 A1 CL 2018003509A1 CL 2018003509 A CL2018003509 A CL 2018003509A CL 2018003509 A CL2018003509 A CL 2018003509A CL 2018003509 A1 CL2018003509 A1 CL 2018003509A1
Authority
CL
Chile
Prior art keywords
pharmaceutical combinations
cancer treatment
cancer
treatment
pharmaceutical
Prior art date
Application number
CL2018003509A
Other languages
English (en)
Inventor
Alexander Bausch
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of CL2018003509A1 publication Critical patent/CL2018003509A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN AGONISTA DE PPAR Y UN INHIBIDOR DE P38 PARA USAR EN UN MÉTODO PARA LA PREVENCIÓN, EL RETRASO DE LA PROGRESIÓN O EL TRATAMIENTO DEL CÁNCER.
CL2018003509A 2016-06-08 2018-12-06 Combinaciones farmacéuticas para el tratamiento del cáncer CL2018003509A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16173443 2016-06-08

Publications (1)

Publication Number Publication Date
CL2018003509A1 true CL2018003509A1 (es) 2019-03-15

Family

ID=56132777

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003509A CL2018003509A1 (es) 2016-06-08 2018-12-06 Combinaciones farmacéuticas para el tratamiento del cáncer

Country Status (26)

Country Link
US (2) US11285155B2 (es)
EP (1) EP3468604B1 (es)
JP (2) JP7349790B2 (es)
KR (1) KR102437685B1 (es)
CN (2) CN109414506B (es)
AU (1) AU2017277478B2 (es)
BR (1) BR112018075135A2 (es)
CA (1) CA3023392C (es)
CL (1) CL2018003509A1 (es)
CO (1) CO2018013020A2 (es)
CY (1) CY1124123T1 (es)
DK (1) DK3468604T3 (es)
EA (1) EA201892287A1 (es)
ES (1) ES2866883T3 (es)
HU (1) HUE053648T2 (es)
IL (1) IL263407B (es)
MX (1) MX379026B (es)
MY (1) MY195671A (es)
PE (1) PE20190376A1 (es)
PH (1) PH12018550186A1 (es)
PL (1) PL3468604T3 (es)
PT (1) PT3468604T (es)
SG (1) SG11201809882XA (es)
UA (1) UA123914C2 (es)
WO (1) WO2017211830A1 (es)
ZA (1) ZA201900052B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
AU2017277478B2 (en) * 2016-06-08 2023-03-16 Support-Venture Gmbh Pharmaceutical combinations for treating cancer
CA3033887A1 (en) * 2016-08-17 2018-02-22 Support-Venture Gmbh Method of preventing or treating hearing loss
SG10202101501PA (en) * 2016-08-18 2021-03-30 Intekrin Therapeutics Inc PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) * 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3820526B1 (en) * 2018-07-13 2024-01-24 Kinarus AG Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU2002256615B2 (en) * 2001-02-12 2007-09-13 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
US6852141B2 (en) * 2001-06-06 2005-02-08 Donaldson Company, Inc. Filter element having center piece and methods
CN1771034A (zh) * 2002-01-14 2006-05-10 法马西亚公司 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
DE602004005238T2 (de) 2003-11-13 2007-11-08 F. Hoffmann-La Roche Ag Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
WO2006127678A2 (en) * 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
WO2008151992A2 (en) 2007-06-15 2008-12-18 F. Hoffmann-La Roche Ag A novel process for the preparation of 3-amino-pentan-1,5-diol
EP2379174A4 (en) * 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
CA2789847A1 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
AU2017277478B2 (en) * 2016-06-08 2023-03-16 Support-Venture Gmbh Pharmaceutical combinations for treating cancer

Also Published As

Publication number Publication date
HUE053648T2 (hu) 2021-07-28
IL263407B (en) 2021-09-30
MX379026B (es) 2025-03-10
CN109414506B (zh) 2022-06-03
CY1124123T1 (el) 2022-05-27
US11285155B2 (en) 2022-03-29
KR20190017756A (ko) 2019-02-20
EA201892287A1 (ru) 2019-06-28
CA3023392C (en) 2024-02-06
MY195671A (en) 2023-02-03
JP2022046526A (ja) 2022-03-23
US20190160072A1 (en) 2019-05-30
AU2017277478B2 (en) 2023-03-16
PH12018550186A1 (en) 2019-03-18
CO2018013020A2 (es) 2018-12-28
JP2019517562A (ja) 2019-06-24
UA123914C2 (uk) 2021-06-23
EP3468604B1 (en) 2021-01-20
CA3023392A1 (en) 2017-12-14
EP3468604A1 (en) 2019-04-17
PT3468604T (pt) 2021-04-06
WO2017211830A1 (en) 2017-12-14
MX2018014938A (es) 2019-05-16
ES2866883T3 (es) 2021-10-20
BR112018075135A2 (pt) 2019-03-26
AU2017277478A1 (en) 2018-11-22
US20220175786A1 (en) 2022-06-09
PL3468604T3 (pl) 2021-07-12
KR102437685B1 (ko) 2022-08-29
SG11201809882XA (en) 2018-12-28
PE20190376A1 (es) 2019-03-08
IL263407A (en) 2018-12-31
DK3468604T3 (da) 2021-04-19
CN109414506A (zh) 2019-03-01
JP7349790B2 (ja) 2023-09-25
ZA201900052B (en) 2021-10-27
CN115105601A (zh) 2022-09-27

Similar Documents

Publication Publication Date Title
CL2018003509A1 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018002359A1 (es) Métodos para usar agonistas de fxr
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2017010618A2 (es) Anticuerpos contra icos
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
SV2017005418A (es) Inhibidor de cinasa aurora a
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2019009304A (es) Tratamiento para el cancer.
MX2017009246A (es) Farmaco de combinacion.
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MX2017006806A (es) Extractos titulados de cynara scolymus para uso en el tratamiento del mesotelioma.
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
AR115575A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer